16 September 2026 editorial review · Item
CNK-UT009 investigational cell therapy: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added narrowly described CNK-UT009 cell programme from registry. Retained phase not applicable rather than invented Phase 1; checked target 12, residual C-peptide eligibility, safety/dose-limit objectives and old update date.
- Primary sources checked: NCT07051564 — study record (registry).
- Limits: Precise cell manufacturing, target, pretreatment and product-specific harms are not adequately characterized in the verified source. Current recruitment unconfirmed; no T1D outcomes posted. No additional programme inferred from dual registration.